ClinicalTrials.Veeva

Menu

Modified SALT Score for Alopecia Areata

K

Kasr El Aini Hospital

Status and phase

Unknown
Phase 4

Conditions

Alopecia Areata

Treatments

Other: saline
Drug: Triamcinolone Acetonide

Study type

Interventional

Funder types

Other

Identifiers

NCT04412148
EgymSALT

Details and patient eligibility

About

Patchy Alopecia areata was treated by intralesional steroids for 3 months and was evaluated by percentage of involvement, mSALT score and dermoscopy.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • localized scalp AA ( 2 patches and ≤50% scalp involvement , duration more than 6 months) • patients who did not receive any medication for at least 2 months before starting the study and those who agreed to join the study and signed written consent.

Exclusion criteria

  • • pregnant, and lactating females

    • Alopecia totalis or universalis or ophiasis or cicatritial alopecia
    • Usage of systemic treatment of alopecia areata 2 months prior to the study.
    • Any scalp lesion within the treated area
    • Bleeding diathesis, severe anemia or platelet disorders
    • Medical conditions such as autoimmune diseases.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Double Blind

20 participants in 2 patient groups, including a placebo group

Intralesional Steroids
Active Comparator group
Treatment:
Drug: Triamcinolone Acetonide
Control
Placebo Comparator group
Treatment:
Other: saline

Trial contacts and locations

1

Loading...

Central trial contact

Rana Hilal, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems